Business ❯ Pharmaceutical Industry

Corporate Acquisitions

Mergers and Acquisitions Novartis Sanofi Alliance Pharma Oncology Companies Generic Drug Market Job Losses Johnson & Johnson Biotech Companies

Novartis Says Del‑brax Study Met Endpoints and Reinforced Phase 3 Dosing

Novartis plans a full review of clinical and biomarker data before engaging global regulators to advance the Phase 3 program.

Servier to Acquire Day One Biopharma in $2.5 Billion All-Cash Deal at $21.50 a Share

FDA Approves Novartis’ Itvisma for SMA Patients Ages 2 and Up

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials